Transcriptional E2F1/2/3/6 as potential prognostic biomarkers in cutaneous melanoma.
E2F1/2/3/6
bioinformatics analysis
cutaneous melanoma
database mining
prognostic value
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
08
2020
accepted:
14
11
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
3
2
2021
Statut:
epublish
Résumé
Although the abnormal expression of members of the E2F family has been reported to participate in carcinogenesis in many human types of cancer, the bioinformatics role of the E2F family in melanoma is unknown. This research was designed to detect the expression, methylation, prognostic value and potential effects of the E2F family in melanoma. We investigated E2F family mRNA expression from the Oncomine and GEPIA databases and their methylation status in the MethHC database. Meanwhile, we detected the relative E2F family expression levels by qPCR and immunohistochemistry. Kaplan-Meier Plotter was used to draw survival analysis charts, and gene functional enrichment analyses were applied through cBioPortal database analysis. E2F1/2/3/4/5/6 mRNA and proteins were clearly upregulated in cutaneous melanoma patients, and high expression levels of E2F1/2/3/6 were statistically related to high methylation levels. Increased mRNA expression of E2F1/2/3/6 was related to lower overall survival rates (OS) and disease-free survival (DFS) in cutaneous melanoma cases. Meanwhile, E2F1/2/3/6 carried out these effects through regulating multiple signaling pathways, including the MAPK, PI3K-Akt and p53 signaling pathways. Taking together, our findings suggest that E2F1/2/3/6 could act as potential targets for precision therapy in cutaneous melanoma patients.
Types de publication
Journal Article
Langues
eng
Pagination
420-433Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
BMC Med Genomics. 2012 Jun 29;5:28
pubmed: 22747986
Clin Cancer Res. 2005 Oct 15;11(20):7234-42
pubmed: 16243793
Nucleic Acids Res. 2015 Jan;43(Database issue):D856-61
pubmed: 25398901
J Mol Biol. 2016 Oct 9;428(20):3960-3971
pubmed: 27567532
N Engl J Med. 2003 Nov 20;349(21):2042-54
pubmed: 14627790
Biosci Rep. 2020 Feb 28;40(2):
pubmed: 31990034
Onco Targets Ther. 2018 Aug 30;11:5303-5313
pubmed: 30214236
Oncotarget. 2016 Jul 12;7(28):43295-43314
pubmed: 27175588
Breast Cancer Res. 2014 Dec 02;16(6):486
pubmed: 25440089
Mol Med Rep. 2014 Sep;10(3):1409-15
pubmed: 25017879
Oncotarget. 2017 Dec 13;8(69):114281-114291
pubmed: 29371986
EMBO J. 2004 Dec 8;23(24):4709-16
pubmed: 15538380
Gene Expr. 2008;14(4):207-16
pubmed: 19110720
JCI Insight. 2017 May 18;2(10):
pubmed: 28515357
Mol Med Rep. 2017 Oct;16(4):3783-3790
pubmed: 28731177
Cell Cycle. 2016 Dec;15(23):3183-3190
pubmed: 27753528
Nat Rev Genet. 2002 Jun;3(6):415-28
pubmed: 12042769
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
PeerJ. 2020 Feb 19;8:e8562
pubmed: 32117628
Autophagy. 2018;14(3):518-533
pubmed: 29215322
Nat Rev Clin Oncol. 2019 Sep;16(9):549-562
pubmed: 30967646
Mol Cell Biol. 2014 Sep;34(17):3229-43
pubmed: 24934442
Cell Death Dis. 2018 May 9;9(5):527
pubmed: 29743521
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
J Natl Cancer Inst. 2015 Jun 18;107(9):
pubmed: 26089541
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
BMC Med Genomics. 2008 Apr 28;1:13
pubmed: 18442402
J Transl Med. 2019 May 29;17(1):181
pubmed: 31142321
Cell Cycle. 2017;16(21):2058-2072
pubmed: 28880708
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7
pubmed: 15833814
BMC Cancer. 2018 Dec 3;18(1):1201
pubmed: 30509235
Aging (Albany NY). 2018 May 11;10(5):973-987
pubmed: 29754146
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cancer Sci. 2019 Mar;110(3):1085-1095
pubmed: 30582655
Nucleic Acids Res. 2016 Jan 8;44(1):117-33
pubmed: 26350215
Cell Cycle. 2012 Aug 15;11(16):3067-78
pubmed: 22871739
Oncotarget. 2017 Jun 13;8(24):39443-39459
pubmed: 28467796
Cancer Biol Ther. 2017 Dec 2;18(12):948-957
pubmed: 28278082
Mol Cancer Res. 2015 Sep;13(9):1316-24
pubmed: 26032289
Oncotarget. 2016 Jul 13;8(33):54021-54036
pubmed: 28903320
Ann N Y Acad Sci. 2017 Aug;1401(1):136-149
pubmed: 28891094
BMC Cancer. 2010 Feb 24;10:64
pubmed: 20181230
PLoS One. 2015 Feb 03;10(2):e0116979
pubmed: 25646628
Eur J Cancer. 2005 Nov;41(16):2403-14
pubmed: 16213134
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10545-54
pubmed: 26617764
J Cell Mol Med. 2020 Feb;24(3):2157-2168
pubmed: 31943751
Int J Mol Sci. 2013 Jul 18;14(7):15029-58
pubmed: 23873296
Turk J Biol. 2019 Oct 14;43(5):293-304
pubmed: 31768102
Oncotarget. 2015 Nov 10;6(35):38210-24
pubmed: 26474282
Nucleic Acids Res. 2016 Mar 9;44(12):5557-5570
pubmed: 26961310
Cancer Treat Rev. 2014 Dec;40(10):1153-60
pubmed: 25455730
World J Gastroenterol. 2011 Jan 28;17(4):470-7
pubmed: 21274376
Nat Commun. 2019 Jul 3;10(1):2939
pubmed: 31270324
Expert Rev Mol Diagn. 2015 May;15(5):647-64
pubmed: 25797072